Shineco (NASDAQ:SISI – Get Free Report) and Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and earnings.
Insider & Institutional Ownership
4.1% of Shineco shares are held by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are held by institutional investors. 0.0% of Shineco shares are held by company insiders. Comparatively, 3.0% of Achieve Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
Shineco has a beta of -1.38, indicating that its share price is 238% less volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Shineco | $9.60 million | 0.01 | -$22.45 million | ($204.00) | 0.00 |
| Achieve Life Sciences | N/A | N/A | -$54.65 million | ($1.30) | -3.05 |
Shineco has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Shineco, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Shineco and Achieve Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Shineco | -380.55% | -79.89% | -33.01% |
| Achieve Life Sciences | N/A | -204.14% | -121.36% |
Analyst Ratings
This is a breakdown of current ratings and target prices for Shineco and Achieve Life Sciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Shineco | 1 | 0 | 0 | 0 | 1.00 |
| Achieve Life Sciences | 1 | 0 | 3 | 2 | 3.00 |
Achieve Life Sciences has a consensus target price of $14.67, suggesting a potential upside of 270.37%. Given Achieve Life Sciences’ stronger consensus rating and higher probable upside, analysts plainly believe Achieve Life Sciences is more favorable than Shineco.
Summary
Achieve Life Sciences beats Shineco on 9 of the 14 factors compared between the two stocks.
About Shineco
Shineco, Inc., through its subsidiaries, processes and distributes agricultural produce. It also engages in the growing and cultivation of mulberry trees and silkworm cocoons; distribution of fruit business; and processing and distribution of silk and silk fabrics, as well as other by-products. The company was incorporated in 1997 and is headquartered in Beijing, the People's Republic of China.
About Achieve Life Sciences
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
Receive News & Ratings for Shineco Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shineco and related companies with MarketBeat.com's FREE daily email newsletter.
